Interestingly, uptake of EGFR and HER2 immuno-PET tracers was also lower in tumors treated with combined MET/MEK inhibition, which also corresponded to decreased total levels of HER2, EGFR, and pHER2 in tumor digests, suggesting that treatment may also interfere with the MET-HER2 cross activation (40). This evidence concerns the gene ERBB2 and neoplasm.